Related coverage linked through entity extraction aliases.
Aug 06, 2026
A CML blast phase prognostic score separates patients into three risk groups with distinct survival. Separate AML studies identified circRNA and NFS1/GSDMD biomarkers; a T-ALL study highlighted markers including CD38, CD99, and TRBC1.
May 05, 2026
Novartis introduced new long-term social impact and sustainability targets covering access, global health, emissions, waste and water. The plan includes a 2030 access goal and net-zero across the value chain by 2040.
Apr 22, 2026
Ascentage Pharma said six clinical abstracts were selected for ASCO 2026 and four preclinical studies will be presented at AACR 2026. The presentations feature olverembatinib and other pipeline candidates.
